gvtcx

Contract Award for the provision of H1V-1 LAg-Avidity ElA to Determine Recency of Infection

Public Health England Published 24 Sept 2018 Contracts Finder

key details

Value£38,100
Statuscomplete
Category (CPV) 33141625
RegionLondon
Deadline10 Sept 2018
Contract start21 Sept 2018
Contract end21 Sept 2019
Procedurelimited
SME suitableNo
OCIDocds-b5fd17-571977b1-74d3-40ed-b59c-48d90ccf06e8

Award

SupplierValueDateStatus
Sedia Biosciences Corporation £38,100 20 Sept 2018 active

description

Public Health England (PHE) has awarded a contract for the provision of H1V-1 LAg-Avidity ElA kits to Sedia Biosciences Corporation, which is used to monitor recent HIV infection in people in newly diagnosed with HIV as part of national Surveillances.

To ensure comparability of data, the same assay is required over time to minimise any variation between assays performance. Sedia LAg assays are used to monitor recent infections in the UK. Sedia Biosciences Corporation is the only manufacturer of the Sedia LAg assay. Alternative LAg assays have been shown to have different performance characteristics following evaluation. Sufficient data have been generated on the Sedia LAg assay to confirm that it meets our performance characteristics and that these data are in line with that published by the manufacturer including an MDRI of approx. 130 days at a normalised ODn of 1.5.

Additional information:

VEAT notice details:

OJEU Document Number 2018/S 167-380498

Notice Reference 2018-041795

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
24 Sept 2018 Award (award) · 64977ca2-4d68-4a4a-a6bb-04de76d3b1c8-242367

more from Public Health England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.